2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1700 Treatment-associated acute hyperinflammatory syndrome in TP53-mutated myeloid leukemia

Steven Tessier, MD MS, Jabra Zarka, MD2, Guneet Singh Janda, M.D.3, Patrick Vanderboom, PhD4, Kimberly Langer, CNP5, Elizabeth Reetz, BS6, Reha Patel7, James Foran, FRCPC8, Cecilia Arana Yi, M.D.9, Naseema Gangat, MBBS10, William Hogan, M.B., B.Ch.11, Nelson Leung, MD12, Ronald Go, MD13, Tariq Kewan, MD14, Abhishek Avinash Mangaonkar, MBBS15, Aref Al-Kali, M.D.16, Hassan B Alkhateeb, M.D.17, Antoine N. Saliba, M.D.18, Mithun Shah, MD, PhD19
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Alterations in the TP53 gene are observed in 8-10% of all acute myeloid leukemia (AML) and identify a highly aggressive cancer with particularly poor survival. The bone marrow microenvironment of TP53mut AML is highly immunosuppressive. We previously showed that a subset of AML patients treated with hypomethylating agents and venetoclax (HMA/VEN) developed hemophagocytic lymphohistiocytosis (HLH). TP53mut was markedly enriched (58%) among AML patients with HLH, lending credence to a likely predisposition conferred by TP53mut (Zarka et al., Blood Neoplasia, 2026). We hypothesized that TP53mut AML hyperinflammatory syndrome (HS) has a distinct clinical and cytokine profile compared with non-AML secondary HLH (sHLH).

Methods: Adults with TP53mut AML evaluated at Mayo Clinic between 2015 and 2025 were included. HLH was defined using the HLH-2004 criteria. Plasma cytokines were measured using the clinically validated bead-based multiplex immunoassay (CYPAN, Mayo Clinic Laboratories) and included 12 cytokines: tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, IL-18, interferon (IFN)-α, IFN-β, IFN-γ, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-2 receptor (IL-2R)α. Cytokine profiles were analyzed across four cohorts: (1) plasma obtained at HS diagnosis in patients with TP53mut AML (TP53mut AML-HS; n=14); (2) plasma obtained at AML diagnosis from patients who later developed HS (baseline TP53mut AML; n=5); (3) plasma obtained at AML diagnosis from patients who did not develop HS (TP53mut AML controls, n=5); and (4) patients with non-AML sHLH (n=93). Analyses were performed using Prism v11.0.2.

Results: Among 146 TP53mut AML patients (of which 72 [55%] were exposed to VEN), 14 (9.6%) experienced HS, characterized by non-infectious fever and acute hyperferritinemia.  HLH-2004 diagnostic criteria for HLH were met in 29% of cases. Thirteen of these 14 patients (93%) were exposed to VEN at some point during their treatment course. Eight (57%) of 14 had HS onset during active leukemia-directed treatment. Of these 8 patients, 7 (88%) developed HS during the first 2 cycles of HMA/VEN (median onset 24 days). The remaining 6 patients developed HS at initial AML diagnosis (n=2), while off active treatment (n=1), following intensive chemotherapy but during a treatment gap (n=1), post-allogeneic stem cell transplantation (alloSCT) in remission (n=1), and post-alloSCT at relapse (n=1). At HS diagnosis, ferritin was lower in TP53mut HS compared with sHLH controls (median 5710 vs 12,127 ng/mL, P=0.01), while fibrinogen was higher (median 624.5 vs 271.0 mg/dL, P<0.0001). Critically, in TP53mut AML-HS, the classical interferon signature of HLH was absent: IFN-γ was undetectable in all patients, and TP53mut AML-HS had markedly lower IFN-γ compared with sHLH (median undetectable vs 82 pg/mL; P=0.0007). In addition, IL-10 was markedly lower in TP53mut AML-HS compared with sHLH (median 7 vs 76.8 pg/mL; P<0.0001). Analysis at AML baseline (n=10) and HS diagnosis (n=14) showed marked elevation of TNF-α (median 10 vs 29.9 pg/mL; P<0.0001) and sIL-2Rα (median 1168 vs 4000 pg/mL; P=0.0004), with upward trends in IL-6 (P=0.07) and IL-18 (P=0.07). Finally, we asked if the baseline cytokine profile could distinguish patients who subsequently developed HS. Indeed, the baseline cytokine panel of TP53mut AML-HS was indistinguishable from those who did not (n = 5).

Conclusions: A subset of patients with TP53mut AML developed HS during leukemia-directed treatment. Unlike sHLH, which is characterized by an IFN-γ-driven signature, TP53mut AML-HS was characterized by undetectable IFN-γ, lower IL-10, and markedly elevated TNF-α and sIL-2Rα. Cytokine analysis performed at AML diagnosis did not predict subsequent HS, whereas the cytokine milieu at HS diagnosis was highly proinflammatory. Collectively, our findings suggest that TP53mut AML may give rise to an HS that is clinically and biologically different from sHLH. Detailed characterization of TP53mut AML-HS has potential implications in how the HS should be diagnosed and managed.  

Steven Tessier, MD MS: No relevant conflicts of interest to declare.